The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
The complement pathway as a therapeutic target for neovascular age-related macular degeneration-mediated subretinal fibrosis
Curr Opin Pharmacol. 2024 Mar 30;76:102448. doi: 10.1016/j.coph.2024.102448. Online ahead of print.ABSTRACTNeovascular age-related macular degeneration (nAMD) is the leading cause of blindness in the elderly in developed countries. Intravitreal injection of VEGF inhibitors is the mainstream therapy for nAMD, although nearly 50% of the patients do not respond or respond poorly to the therapy. One of the main reasons for the poor outcome of the therapy is the development of subretinal macular fibrosis, a process of excessive deposition of extracellular matrix proteins around the diseased blood vessels. Currently, there is no...
Source: Current Opinion in Pharmacology - March 31, 2024 Category: Drugs & Pharmacology Authors: Heping Xu Caijiao Yi Mei Chen Source Type: research
Targeting TRP channels for pain relief: A review of current evidence from bench to bedside
Curr Opin Pharmacol. 2024 Apr;75:102447. doi: 10.1016/j.coph.2024.102447. Epub 2024 Mar 11.ABSTRACTSeveral decades of research support the involvement of transient receptor potential (TRP) channels in nociception. Despite the disappointments of early TRPV1 antagonist programs, the TRP family remains a promising therapeutic target in pain disorders. High-dose capsaicin patches are already in clinical use to relieve neuropathic pain. At present, localized injections of the side-directed TRPV1 agonist capsaicin and resiniferatoxin are undergoing clinical trials in patients with osteoarthritis and bone cancer pain. TRPA1, TRPM...
Source: Current Opinion in Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Authors: Ari-Pekka Koivisto Thomas Voets Michael J Iadarola Arpad Szallasi Source Type: research
Targeting TRP channels for pain relief: A review of current evidence from bench to bedside
Curr Opin Pharmacol. 2024 Apr;75:102447. doi: 10.1016/j.coph.2024.102447. Epub 2024 Mar 11.ABSTRACTSeveral decades of research support the involvement of transient receptor potential (TRP) channels in nociception. Despite the disappointments of early TRPV1 antagonist programs, the TRP family remains a promising therapeutic target in pain disorders. High-dose capsaicin patches are already in clinical use to relieve neuropathic pain. At present, localized injections of the side-directed TRPV1 agonist capsaicin and resiniferatoxin are undergoing clinical trials in patients with osteoarthritis and bone cancer pain. TRPA1, TRPM...
Source: Current Opinion in Pharmacology - March 12, 2024 Category: Drugs & Pharmacology Authors: Ari-Pekka Koivisto Thomas Voets Michael J Iadarola Arpad Szallasi Source Type: research
